Program
Anti-CD46 Antibody-drug Conjugate FOR46
Also written as “FOR46” and “FG-3246”.
Its studies are mostly in Prostatic Neoplasms · Multiple Myeloma, led by 2 companies.
Drug pageAnti-CD46 Antibody-drug Conjugate FOR46: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Fortis Therapeuticsits history only | 20 open or running | phase 1since Jun 20, 2018 | Jun 20, 2018 | none ahead |
| Kyntra Bioits history only | 11 open or running | phase 2since Feb 19, 2025 | Feb 19, 2025 | Mar 31, 2028phase 2 · NCT06842498 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 20, 2018First study: phase 1 study in Prostate Cancer MetastaticNew to Fortis TherapeuticsFortis Therapeutics · NCT03575819 · 56 enrolled · United States
- Aug 21, 2018Phase 1 study in Multiple MyelomaFortis Therapeutics · NCT03650491 · 31 enrolled · United States
- Feb 19, 2025Kyntra Bio’s first study: phase 2 study in Prostatic NeoplasmsNew to Kyntra BioKyntra Bio · NCT06842498 · 75 planned · United States
Ahead
- Mar 31, 2028Primary completion: phase 2 study in Prostatic NeoplasmsKyntra Bio · NCT06842498
TargetBeta
“An antibody-drug conjugate (ADC) composed of a human monoclonal antibody directed against the cluster of differentiation 46 (CD46; membrane cofactor protein; MCP) and ”NCIt, by rule
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06842498Prostatic Neoplasms · United States | 2 | Recruiting | Kyntra Bio | Mar 31, 2028 | 75 |
| NCT03650491Multiple Myeloma · United States | 1 | Completed | Fortis Therapeutics | Jan 31, 2022 | 31 |
| NCT03575819Prostate Cancer Metastatic · United States | 1 | Completed | Fortis Therapeutics | Nov 16, 2023 | 56 |
How it is read
Names in the registry
- “FOR46”, 2 entries
- “FG-3246”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 2 studies
- Multiple Myeloma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.